公开(公告)号：US20250002581A1

公开(公告)日：2025-01-02

申请号：US18710523

申请日：2022-11-15

Applicant: Versitech Limited

Inventor： Zhiwei Chen ,  Dongyan Zhou ,  Li Liu

IPC: C07K16/28 ,  A61K39/00 ,  A61P37/04

Abstract: Provided are two fully humanized Δ42PD1-specific mAbs, specifically huCH101 and huCH34 at 97.0% humanness by CDR grafting. Provided is a method of using huCH101 and/or huCH34 to treat subjects in need of Δ42PD1-specific mAb, including subjects with cancer and/or infection.

公开(公告)号：US12018063B2

公开(公告)日：2024-06-25

申请号：US17186822

申请日：2021-02-26

Applicant: Versitech Limited

Inventor： Zhiwei Chen ,  Kwok Yung Yuen ,  Honglin Chen ,  Yik Chun Wong ,  Li Liu

IPC: C07K14/705 ,  A61K39/12 ,  A61P31/14 ,  C07K14/165

CPC classification number: C07K14/70521 ,  C07K14/165 ,  C07K2319/30

Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.